| Name | Title | Contact Details |
|---|---|---|
Craig Malzahn |
Chief Technology Officer | Profile |
Curran Simpson |
Chief Operating Officer | Profile |
We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
Vivakor is a Coralville, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.